Lakefront Biotherapeutics NV annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lakefront Biotherapeutics NV Stock-Based Compensation Growth & History (LKFT)
Lakefront Biotherapeutics NV's stock-based compensation was €24.0M for fiscal 2025.
View full Lakefront Biotherapeutics NV company overviewLakefront Biotherapeutics NV annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €24.0M | €4.1M | +20.68% |
| 2024 | 2024-12-31 | €19.9M | −€36.8M | −64.94% |
| 2023 | 2023-12-31 | €56.7M | −€31.8M | −35.92% |
| 2022 | 2022-12-31 | €88.5M | €17.8M | +25.14% |
| 2021 | 2021-12-31 | €70.7M | −€9.2M | −11.55% |
| 2020 | 2020-12-31 | €80.0M | €41.7M | +108.79% |
| 2019 | 2019-12-31 | €38.3M | €11.5M | +43.13% |
| 2018 | 2018-12-31 | €26.8M | €10.2M | +61.81% |
| 2017 | 2017-12-31 | €16.5M | €5.5M | +49.86% |
| 2016 | 2016-12-31 | €11.0M | €6.0M | +119.10% |
| 2015 | 2015-12-31 | €5.0M | — | — |
Lakefront Biotherapeutics NV stock-based compensation trends
Over the last five fiscal years, Lakefront Biotherapeutics NV's stock-based compensation decreased from €80.0M to €24.0M, a change of −€56.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakefront Biotherapeutics NV source filings ↗